Methods of administering safe colon cleansing compositions
Summary
USPTO granted patent US12594298B2 to Azurity Pharmaceuticals covering methods of administering colon cleansing compositions. The patent protects formulations comprising salt mixtures that induce purgation without requiring adjunct laxatives like bisacodyl, offering improved tolerability and patient compliance. The patent names Edmund V. Dennett, Mark Cleveland, Russell W. Pelham, and Matthew Walker as inventors, with 3 claims allowed.
What changed
USPTO issued patent grant US12594298B2 to Azurity Pharmaceuticals, Inc. for methods of administering colon cleansing compositions. The patent covers salt-based purgative formulations that prevent PEG degradation and eliminate the need for stimulant laxatives, with claimed advantages in tolerability, safety, and patient compliance. The grant date is April 7, 2026, with application number 19172077.
Affected parties should monitor this IP development as it grants Azurity exclusive rights to these colon cleansing methods. Competitors developing similar purgative formulations may need to design around these claims or seek licensing. Healthcare providers and pharmaceutical companies in the GI/colon cleansing space should assess whether their products or development programs fall within the scope of these protected methods.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of administering safe colon cleansing compositions
Grant US12594298B2 Kind: B2 Apr 07, 2026
Assignee
Azurity Pharmaceuticals, Inc.
Inventors
Edmund V. Dennett, Mark Cleveland, Russell W. Pelham, Matthew Walker
Abstract
Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
CPC Classifications
A61K 31/765 A61K 9/08 A61K 33/04 A61K 47/02 A61P 1/10
Filing Date
2025-04-07
Application No.
19172077
Claims
3
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.